Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Transarterial chemoembolization (TACE) is the most performed endovascular interventional radiology (IR) procedure. TACE procedures are performed in an IR suite, most of which are equipped with floor-based flat-panel robotic C-arm allowing two-dimensional imaging. Cone-beam computed tomography (CBCT) has been developed to allow three-dimensional navigation but has several limitations such as reduced signal to noise ratio and small field-of-view, and seems to have negative impact on patient radiation exposure. Another option to perform 3D imaging is called angio-CT which combines a CT-scan and a floor-based flat-panel robotic C-arm in a single IR suite. Even if some publications have shown benefit of angio-CT in TACE procedures in Japan, no study about angio-CT in liver IR procedures has been conducted in the occidental world so far. The purpose of our study was to assess the impact of angio-CT use on patient radiation exposure and treatment quality in TACE procedures compared to CBCT.
This before-after study consisted of a review of consecutive TACE procedures performed between January 2016 and September 2017 in our institution with two different imaging modalities, defining two study groups (C-arm with CBCT versus angio-CT).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Patient effective radiation dose per TACE | Patient effective radiation dose (mSv) per TACE : Dose-area product (in mGy/cm^2) and dose-length product (in mGy/cm) will be combined and converted to report effective dose (in mSv). | 1 day |
| Measure | Description | Time Frame |
|---|---|---|
| Air kerma per TACE | Air kerma (in mGy) per TACE | 1 day |
| Fluoroscopy time per TACE | Fluoroscopy time (in sec) per TACE | 1 day |
Not provided
Inclusion criteria:
Exclusion criteria:
- TACE not performed
Not provided
Not provided
Not provided
TACE sessions performed on adult patients with primary or secondary liver tumor(s) after multidisciplinary tumor meeting approval
Not provided
| Name | Affiliation | Role |
|---|---|---|
| BORIS GUIU, PU-PH | University Hospital, Montpellier | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Uhmontpellier | Montpellier | 34295 | France |
NC
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006528 | Carcinoma, Hepatocellular |
| ID | Term |
|---|---|
| D000230 | Adenocarcinoma |
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
Not provided
Not provided
Not provided
Not provided
Not provided
| Number of CBCT acquisitions per TACE | Number of CBCT acquisitions per TACE | 1 day |
| Number of CT acquisitions per TACE | Number of CT acquisitions per TACE | 1 day |
| Treatment targeting | Assessed on control CBCT or CT and graded into 3 classes : fully targeted, partially targeted or untargeted. | 1 day |
| Tumor response | Assessed on follow-up CT or MRI and graded into 3 classes : response, tumor stability or progression. | 1 day |
| D009369 | Neoplasms |
| D008113 | Liver Neoplasms |
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
| D004066 | Digestive System Diseases |
| D008107 | Liver Diseases |